ELDN - Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals Inc Logo

ELDN - Eledon Pharmaceuticals Inc

https://eledon.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-10 (Snapshot)

Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral sclerosis (ALS) who require organ or cell transplantation. The company is headquartered in Irvine, California.

52W High
$5.54
52W Low
$2.38
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
-0.12
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
4.17
Forward P/E (<15 better)
5.39
EV/EBITDA (<8 favorable)
0.84
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
3.22
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
1.40%
Institutions (25–75% balanced)
72.25%
Shares Outstanding
59,882,000
Float
39,758,300
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
0.65
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
0.30%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.1187
Previous
-0.1066
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025